Showing 9,701 - 9,720 results of 18,660 for search 'significantly ((((mean decrease) OR (((nn decrease) OR (a decrease))))) OR (observed decrease))', query time: 0.49s Refine Results
  1. 9701

    Statistics of reads aligned to gene structure. by Chaoyun Yang (11523358)

    Published 2025
    “…The results of transcriptome sequencing demonstrated that the overexpression of the HADHB gene markedly altered the transcriptional profile of preadipocytes, with 170 genes exhibiting a significant increase in expression and 113 genes displaying a decrease. …”
  2. 9702

    Protocols for real-time quantitative PCR. by Chaoyun Yang (11523358)

    Published 2025
    “…The results of transcriptome sequencing demonstrated that the overexpression of the HADHB gene markedly altered the transcriptional profile of preadipocytes, with 170 genes exhibiting a significant increase in expression and 113 genes displaying a decrease. …”
  3. 9703

    The Original gel map protein immunoblotting. by Chaoyun Yang (11523358)

    Published 2025
    “…The results of transcriptome sequencing demonstrated that the overexpression of the HADHB gene markedly altered the transcriptional profile of preadipocytes, with 170 genes exhibiting a significant increase in expression and 113 genes displaying a decrease. …”
  4. 9704
  5. 9705

    DataSheet4_Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study.pdf by Yongming Du (807059)

    Published 2024
    “…Background<p>Observational studies suggest the risk of primary ovarian insufficiency (POI) is increased in autoimmune disorders (AIDs), but it is unclear whether there is a causal relationship. …”
  6. 9706

    DataSheet7_Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study.pdf by Yongming Du (807059)

    Published 2024
    “…Background<p>Observational studies suggest the risk of primary ovarian insufficiency (POI) is increased in autoimmune disorders (AIDs), but it is unclear whether there is a causal relationship. …”
  7. 9707

    DataSheet9_Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study.docx by Yongming Du (807059)

    Published 2024
    “…Background<p>Observational studies suggest the risk of primary ovarian insufficiency (POI) is increased in autoimmune disorders (AIDs), but it is unclear whether there is a causal relationship. …”
  8. 9708

    DataSheet6_Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study.pdf by Yongming Du (807059)

    Published 2024
    “…Background<p>Observational studies suggest the risk of primary ovarian insufficiency (POI) is increased in autoimmune disorders (AIDs), but it is unclear whether there is a causal relationship. …”
  9. 9709

    DataSheet1_Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study.pdf by Yongming Du (807059)

    Published 2024
    “…Background<p>Observational studies suggest the risk of primary ovarian insufficiency (POI) is increased in autoimmune disorders (AIDs), but it is unclear whether there is a causal relationship. …”
  10. 9710

    DataSheet3_Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study.pdf by Yongming Du (807059)

    Published 2024
    “…Background<p>Observational studies suggest the risk of primary ovarian insufficiency (POI) is increased in autoimmune disorders (AIDs), but it is unclear whether there is a causal relationship. …”
  11. 9711

    DataSheet5_Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study.pdf by Yongming Du (807059)

    Published 2024
    “…Background<p>Observational studies suggest the risk of primary ovarian insufficiency (POI) is increased in autoimmune disorders (AIDs), but it is unclear whether there is a causal relationship. …”
  12. 9712

    DataSheet2_Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study.pdf by Yongming Du (807059)

    Published 2024
    “…Background<p>Observational studies suggest the risk of primary ovarian insufficiency (POI) is increased in autoimmune disorders (AIDs), but it is unclear whether there is a causal relationship. …”
  13. 9713

    DataSheet8_Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study.zip by Yongming Du (807059)

    Published 2024
    “…Background<p>Observational studies suggest the risk of primary ovarian insufficiency (POI) is increased in autoimmune disorders (AIDs), but it is unclear whether there is a causal relationship. …”
  14. 9714

    Table 1_Prevalence and prognostic value of sarcopenia in patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.docx by Lei Zhang (38117)

    Published 2025
    “…</p>Conclusion<p>Sarcopenia is commonly observed among patients with bladder cancer and appears to be an important prognostic indicator associated with decreased OS and CSS in those undergoing radical cystectomy. …”
  15. 9715

    Image 1_Ticagrelor vs. clopidogrel in dual antiplatelet therapy after coronary artery bypass surgery: a meta-analysis.tif by Liyuan Wang (795570)

    Published 2025
    “…A + T was associated with a decreased risk of all-cause mortality (OR = 0.47, 95% CI 0.31–0.70, p < 0.001, p heterogeneity = 0.80, I<sup>2</sup> = 0%) and cardiovascular mortality (OR = 0.50, 95% CI 0.31–0.82, p = 0.006, p heterogeneity = 0.71, I<sup>2</sup> = 0%), compared with A + C group. …”
  16. 9716

    Image 2_Ticagrelor vs. clopidogrel in dual antiplatelet therapy after coronary artery bypass surgery: a meta-analysis.tif by Liyuan Wang (795570)

    Published 2025
    “…A + T was associated with a decreased risk of all-cause mortality (OR = 0.47, 95% CI 0.31–0.70, p < 0.001, p heterogeneity = 0.80, I<sup>2</sup> = 0%) and cardiovascular mortality (OR = 0.50, 95% CI 0.31–0.82, p = 0.006, p heterogeneity = 0.71, I<sup>2</sup> = 0%), compared with A + C group. …”
  17. 9717

    Table 1_A national population-based study of mortality and risk factors in COVID-19-hospitalized patients in Spain (2020–2021).docx by José-Manuel Ramos-Rincón (10428656)

    Published 2025
    “…IHM rose with age, from 0.8% in patients aged 18–39 to 31.7% in those ≥80 years (p < 0.001), but significant decreases were observed across all age groups after vaccination, especially in those ≥80 years (AOR: 0.76, 95% CI: 0.75–0.79, p < 0.001). …”
  18. 9718

    Data Sheet 2_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  19. 9719

    Data Sheet 1_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  20. 9720

    Supplementary Material for: The risk of cardiovascular disease following aromatase inhibitor therapy for breast cancer in postmenopausal women: a systematic review and meta-analysi... by figshare admin karger (2628495)

    Published 2025
    “…However, there was a significant decrease in the risk of myocardial infarction (RR 0.77, 95% CI: 0.65-0.90, p<0.05) in the AI group when compared to no hormonal treatment. …”